April 1, 2013
The European Medicines Agency (EMA) accepted on March 26 local time the marketing authorization application (MAA) for ospemifene submitted by London-based Shionogi Limited, its parent company Shionogi & Co. in Japan announced on March 27. Shionogi expects ospemifene, a drug...read more